Schrodinger Inc. (SDGR): Price and Financial Metrics
SDGR Price/Volume Stats
| Current price | $24.81 | 52-week high | $59.24 |
| Prev. close | $24.49 | 52-week low | $20.76 |
| Day low | $24.36 | Volume | 654,500 |
| Day high | $25.63 | Avg. volume | 852,338 |
| 50-day MA | $27.06 | Dividend yield | N/A |
| 200-day MA | $31.59 | Market Cap | 1.79B |
SDGR Stock Price Chart Interactive Chart >
Schrodinger Inc. (SDGR) Company Bio
Schrödinger, Inc. provides chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development
Latest SDGR News From Around the Web
Below are the latest news stories about SCHRODINGER INC that investors may wish to consider to help them evaluate SDGR as an investment opportunity.
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NEW YORK, December 19, 2023--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on December 13, 2023, the company granted (i) non-statutory stock options to purchase 1,800 shares of the company’s common stock to three newly hired employees and (ii) restricted stock units (RSUs) with respect to 2,250 shares of the company’s common stock to three newly hired employees. These grants were |
Schrödinger Highlights Progress of Clinical Programs and Discloses Three New Programs at First Therapeutics Pipeline Investor EventNEW YORK, December 14, 2023--Schrödinger is providing a detailed review of its proprietary drug discovery and development programs during its Pipeline Day. |
Artificial Intelligence in Healthcare: 3 Stocks Transforming the IndustryCompanies are applying AI in healthcare which is leading to better outcomes and stronger performance for their stocks. |
Schrödinger Presents Data Supporting Advancement of SGR-1505 and SGR-2921 at American Society of Hematology 2023 Annual MeetingNEW YORK, December 10, 2023--Schrödinger today announced new preclinical data on SGR-1505, its investigational MALT1 inhibitor, and SGR-2921, its investigational CDC7 inhibitor. |
Micro/Small Cap Companies Using AI In Drug Discovery Up 35% In NovemberThe AI method is up to 250 times more efficient than the traditional method of drug discovery. reducing timelines for drug discovery, increasing accuracy of efficacy and safety predictions. |
SDGR Price Returns
| 1-mo | -7.32% |
| 3-mo | -8.62% |
| 6-mo | 11.51% |
| 1-year | -15.55% |
| 3-year | -67.22% |
| 5-year | N/A |
| YTD | -30.70% |
| 2023 | 91.55% |
| 2022 | -46.34% |
| 2021 | -56.01% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...